Dare Bioscience (DARE) Projected to Post Quarterly Earnings on Thursday

Dare Bioscience (NASDAQ:DARE) is projected to release its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect Dare Bioscience to post earnings of ($0.33) per share and revenue of $0.01 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.

Dare Bioscience (NASDAQ:DARE) last announced its earnings results on Thursday, August 14th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.10. The company had revenue of ($0.02) million for the quarter, compared to analysts’ expectations of $0.14 million. On average, analysts expect Dare Bioscience to post $0 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Dare Bioscience Trading Up 6.6%

NASDAQ DARE opened at $1.94 on Wednesday. The firm has a market capitalization of $26.15 million, a P/E ratio of -0.91 and a beta of 1.14. The business has a fifty day simple moving average of $2.07 and a 200 day simple moving average of $2.42. Dare Bioscience has a 12 month low of $1.76 and a 12 month high of $9.19.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on DARE shares. Wall Street Zen upgraded shares of Dare Bioscience to a “hold” rating in a research note on Saturday, August 16th. Maxim Group upgraded shares of Dare Bioscience from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a report on Thursday, September 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dare Bioscience in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $10.00.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.